The purpose of this study is to evaluate the efficacy of an everolimus conversion (EVR)
protocol as compared to the standard tacrolimus (TAC) based protocol in liver transplant
recipients, as determined by renal function, rejection rates, and progression to fibrosis (in
HCV positive subjects). Additionally, safety profile and tolerability of these regimens will
be assessed.